Affymax
Latest round
- Series E
Last raised
- Apr 2006
Total raised
- $70M
Investors
- 9
About Affymax
Affymax Inc.Founded in 2001 in Palo Alto, US, Affymax Inc. focuses on creating groundbreaking treatments for anemia and has undergone significant development since its inception.7 million shares offered at an exit price of USD 25 on the NASDAQ.Affymax Inc. offers innovative biopharmaceutical products aimed primarily at addressing anemia associated with chronic kidney disease. Their lead product is designed to stimulate erythropoiesis, improving hemoglobin levels in patients. The company aims to expand its market presence, particularly in North America and Europe, by enhancing its sales and marketing capabilities. The strategic allocation of funds will support the development of additional products and facilitate entry into new geographical regions, enhancing the overall portfolio of solutions offered to healthcare providers.
Who invested in Affymax
9 investors across 2 rounds
See all investors in Affymax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Affymax
Who invested in Affymax?
Affymax has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Affymax raised?
Affymax has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Affymax last raise money?
Affymax's most recent round on record is a Series E, in Apr 2006.
What does Affymax do?
Affymax is a pharmaceuticals company.
Where is Affymax headquartered?
Affymax is headquartered in Palo Alto, US.
Which VCs invest in companies like Affymax?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Affymax's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series E
Raising like Affymax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.